CVRx to Present at the Jefferies Global Healthcare Conference in London
CVRx (NASDAQ: CVRX) announced that management will present at the Jefferies Global Healthcare Conference in London on Tuesday, Nov 18, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CVRx (NASDAQ: CVRX) announced that management will present at the Jefferies Global Healthcare Conference in London on Tuesday, Nov 18, 2025.
The presentation is scheduled for 8:00 a.m. GMT / 4:00 a.m. ET and will be available live via audio webcast on the company investor relations site at ir.cvrx.com.
Details
News Market Reaction – CVRX
On Nov 4, the day this news came out, CVRX closed 3.57% below the previous close.
Data tracked by StockTitan Argus for the Nov 4 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MINNEAPOLIS, Nov. 04, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the Jefferies Global Healthcare Conference in London on Tuesday, Nov. 18, 2025. The Company is scheduled to present at 8:00 a.m. (GMT) / 4:00 a.m. (ET) the same day via webcast.
A live audio webcast of the conference presentation will be available online at the investor relations page of the Company’s website at ir.cvrx.com.
About CVRx, Inc.
CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.
Investor Contact:
Mark Klausner or Mike Vallie
ICR Healthcare
443-213-0501
ir@cvrx.com
Media Contact:
Emily Meyers
CVRx, Inc.
763-416-2853
emeyers@cvrx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.